Long-Term Exposure to Air Pollution and COVID-19 Vaccine Antibody Response in a General Population Cohort (COVICAT Study, Catalonia).


Journal

Environmental health perspectives
ISSN: 1552-9924
Titre abrégé: Environ Health Perspect
Pays: United States
ID NLM: 0330411

Informations de publication

Date de publication:
04 2023
Historique:
medline: 7 4 2023
entrez: 5 4 2023
pubmed: 6 4 2023
Statut: ppublish

Résumé

Ambient air pollution has been associated with COVID-19 disease severity and antibody response induced by infection. We examined the association between long-term exposure to air pollution and vaccine-induced antibody response. This study was nested in an ongoing population-based cohort, COVICAT, the GCAT-Genomes for Life cohort, in Catalonia, Spain, with multiple follow-ups. We drew blood samples in 2021 from 1,090 participants of 2,404 who provided samples in 2020, and we included 927 participants in this analysis. We measured immunoglobulin M (IgM), IgG, and IgA antibodies against five viral-target antigens, including receptor-binding domain (RBD), spike-protein (S), and segment spike-protein (S2) triggered by vaccines available in Spain. We estimated prepandemic (2018-2019) exposure to fine particulate matter [PM Among vaccinated persons not infected by SARS-CoV-2 ( Exposure to air pollution was associated with lower COVID-19 vaccine antibody response. The implications of this association on the risk of breakthrough infections require further investigation. https://doi.org/10.1289/EHP11989.

Sections du résumé

BACKGROUND
Ambient air pollution has been associated with COVID-19 disease severity and antibody response induced by infection.
OBJECTIVES
We examined the association between long-term exposure to air pollution and vaccine-induced antibody response.
METHODS
This study was nested in an ongoing population-based cohort, COVICAT, the GCAT-Genomes for Life cohort, in Catalonia, Spain, with multiple follow-ups. We drew blood samples in 2021 from 1,090 participants of 2,404 who provided samples in 2020, and we included 927 participants in this analysis. We measured immunoglobulin M (IgM), IgG, and IgA antibodies against five viral-target antigens, including receptor-binding domain (RBD), spike-protein (S), and segment spike-protein (S2) triggered by vaccines available in Spain. We estimated prepandemic (2018-2019) exposure to fine particulate matter [PM
RESULTS
Among vaccinated persons not infected by SARS-CoV-2 (
DISCUSSION
Exposure to air pollution was associated with lower COVID-19 vaccine antibody response. The implications of this association on the risk of breakthrough infections require further investigation. https://doi.org/10.1289/EHP11989.

Identifiants

pubmed: 37017430
doi: 10.1289/EHP11989
pmc: PMC10075082
doi:

Substances chimiques

Air Pollutants 0
COVID-19 Vaccines 0
Particulate Matter 0
Nitrogen Dioxide S7G510RUBH
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

47001

Références

BMJ Open. 2018 Mar 27;8(3):e018324
pubmed: 29593016
Eur Respir J. 2022 Jul 26;:
pubmed: 35896215
Environ Int. 2021 Sep;154:106564
pubmed: 33964723
CMAJ. 2022 May 24;194(20):E693-E700
pubmed: 35609912
Curr Environ Health Rep. 2022 Sep;9(3):477-489
pubmed: 35648356
EMBO Mol Med. 2022 May 9;14(5):e15326
pubmed: 35393790
Free Radic Biol Med. 2020 May 1;151:56-68
pubmed: 32007522
Environ Sci Technol. 2012 Oct 16;46(20):11195-205
pubmed: 22963366
Environ Res. 2020 Aug;187:109650
pubmed: 32416357
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
Transl Res. 2021 Jun;232:60-74
pubmed: 33582244
Zentralbl Hyg Umweltmed. 1994 Jun;195(5-6):457-62
pubmed: 7916873
Mucosal Immunol. 2022 May;15(5):799-808
pubmed: 35468942
Int J Environ Res Public Health. 2021 Jun 11;18(12):
pubmed: 34208042
Nat Commun. 2022 Feb 16;13(1):907
pubmed: 35173150
Environ Pollut. 2022 Sep 1;308:119686
pubmed: 35779662
JAMA Netw Open. 2022 Apr 1;5(4):e228109
pubmed: 35442452
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
EBioMedicine. 2022 Jan;75:103805
pubmed: 35032961
JAMA. 2012 Jan 25;307(4):391-7
pubmed: 22274686
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
MAbs. 2022 Jan-Dec;14(1):2031483
pubmed: 35220888
Environ Int. 2018 Nov;120:81-92
pubmed: 30075373
Environ Adv. 2022 Oct;9:100270
pubmed: 35912397
BMC Med. 2022 Sep 16;20(1):347
pubmed: 36109713
Environ Pollut. 2022 Aug 1;306:119442
pubmed: 35568291
Redox Biol. 2020 Jul;34:101545
pubmed: 32505541
J Nutr. 2011 Jun;141(6):1140-5
pubmed: 21508208
Science. 2021 Jan 29;371(6528):464-465
pubmed: 33510014
Environ Sci Pollut Res Int. 2022 Feb;29(9):13720-13728
pubmed: 34599446
Gac Sanit. 2021 Mar-Apr;35(2):113-122
pubmed: 32014314
Nat Immunol. 2020 Dec;21(12):1486-1495
pubmed: 33046888
Environ Health Perspect. 2020 Sep;128(9):95001
pubmed: 32902328
Vaccines (Basel). 2020 Nov 02;8(4):
pubmed: 33147686
Sci Rep. 2021 Nov 3;11(1):21571
pubmed: 34732749
Am J Respir Crit Care Med. 2022 Aug 15;206(4):440-448
pubmed: 35537137
Environ Health Perspect. 2022 Nov;130(11):117006
pubmed: 36367781
Environ Health Perspect. 2021 Nov;129(11):117003
pubmed: 34787480
J Infect Dis. 2021 Mar 29;223(6):957-970
pubmed: 33367897

Auteurs

Manolis Kogevinas (M)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Spain.

Marianna Karachaliou (M)

Barcelona Institute for Global Health, Barcelona, Spain.

Ana Espinosa (A)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Spain.

Ruth Aguilar (R)

Barcelona Institute for Global Health, Barcelona, Spain.

Gemma Castaño-Vinyals (G)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.
Hospital del Mar Medical Research Institute, Barcelona, Spain.

Judith Garcia-Aymerich (J)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.

Anna Carreras (A)

Genomes for Life-GCAT lab Group, Germans Trias i Pujol Research Institute, Badalona, Spain.

Beatriz Cortés (B)

Genomes for Life-GCAT lab Group, Germans Trias i Pujol Research Institute, Badalona, Spain.

Vanessa Pleguezuelos (V)

Banc de Sang i Teixits, Barcelona, Spain.

Kyriaki Papantoniou (K)

Department of Epidemiology, Center of Public Health, Medical University of Vienna, Vienna, Austria.

Rocío Rubio (R)

Barcelona Institute for Global Health, Barcelona, Spain.

Alfons Jiménez (A)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.

Marta Vidal (M)

Barcelona Institute for Global Health, Barcelona, Spain.

Pau Serra (P)

Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain.

Daniel Parras (D)

Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain.

Pere Santamaría (P)

Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain.
Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Luis Izquierdo (L)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Enfermedades Infecciosas, Barcelona, Spain.

Marta Cirach (M)

Barcelona Institute for Global Health, Barcelona, Spain.

Mark Nieuwenhuijsen (M)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.

Payam Dadvand (P)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.

Kurt Straif (K)

Barcelona Institute for Global Health, Barcelona, Spain.

Gemma Moncunill (G)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Enfermedades Infecciosas, Barcelona, Spain.

Rafael de Cid (R)

Genomes for Life-GCAT lab Group, Germans Trias i Pujol Research Institute, Badalona, Spain.

Carlota Dobaño (C)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Enfermedades Infecciosas, Barcelona, Spain.

Cathryn Tonne (C)

Barcelona Institute for Global Health, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública, Madrid, Spain.
Universitat Pompeu Fabra, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH